Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma

Role of the IL-2 Inducible Tcell Kinase in EBV-HLH and EBV+ Hodgkin's Lymphoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01490801

Enrollment

Registered

2011-12-13

Start date

2011-12-31

Completion date

2016-05-31

Last updated

2016-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, Nonneoplastic Condition

Keywords

childhood Hodgkin lymphoma, childhood mixed cellularity Hodgkin lymphoma, hemophagocytic lymphohistiocytosis, Epstein-Barr virus infection

Brief summary

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies biomarkers in blood and tissue samples from patients with Epstein-Barr virus positive Hodgkin lymphoma.

Detailed description

OBJECTIVES: * Evaluate germline DNA from patients with Epstein-Barr virus positive (EBV+) and Hodgkin lymphoma (HL) for inducible T-cell kinase (ITK) mutations. * Examine the effects of ITK mutations on expression of the ITK protein. * Determine whether ITK mutations correlate with specific clinical or histopathological features of HL. OUTLINE: Archived blood and tumor tissue samples are analyzed for germline DNA expression and inducible T-cell kinase (ITK) mutations by PCR, IHC, flow cytometry, and western blotting, and EBV-encoded RNA (EBER) using in situ hybridization. Each patient's data, such as date, sex, age, tumor stage and histology at diagnosis, treatment received, response to treatment, development of recurrent disease, date of last follow-up, and outcomes are also collected.

Interventions

OTHERimmunohistochemistry staining method

OTHERmedical chart review

OTHERflow cytometry

GENETICDNA analysis

GENETICRNA analysis

GENETICcytogenetic analysis

GENETICin situ hybridization

GENETICmutation analysis

GENETICpolymerase chain reaction

GENETICwestern blotting

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 9 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of Hodgkin lymphoma (HL) meeting the following criteria: * Epstein-Barr virus-positive (EBV+) HL as assessed by positive EBV serology, elevated levels of EBV genome in the blood or tumor tissue following quantitative polymerase chain reaction (PCR) and/or evidence of EBV positivity of pathology samples (EBER+ or LMP+) and, when possible, mixed cellular histology * Young age (\< 10 years) at diagnosis * Presence of hemophagocytic lymphohistiocytosis (HLH) PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

Measure	Time frame
Presence of germline ITK mutations	—
Influence of ITK mutations on total expression levels or intracellular localization of the ITK protein	—
Correlation between ITK mutations with specific clinical or histopathological features of HL	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026